Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsJordan Sloshower, MD, MSc
Clinical InstructorDownloadHi-Res Photo
About
Copy Link
Biography
Jordan Sloshower, MD, MSc is a board certified psychiatrist, researcher, and educator whose work focuses on therapeutic applications of psychedelic medicines, and in particular, how these novel treatments can be integrated with psychotherapy and other healing modalities to promote holistic healing. He is currently a faculty member in the Yale Department of Psychiatry, where he co-founded the Yale Psychedelic Science Group and served as an investigator and therapist in several clinical trials of psilocybin-assisted therapy. Jordan is co-founder and co-director of West Rock Wellness PLLC, an interdisciplinary and integrative mental health center in New Haven, CT. He is also Chief Medical Officer at Beckley Clinical, whose mission is to integrate ketamine-assisted psychotherapy (KAP) with holistic mental health interventions to improve patient outcomes in real-world clinical settings. Reflecting his commitment to ethical stewardship of psychedelic medicines, Jordan serves as a member of Chacruna Institute’s advisory board and was a part of the inaugural Board of Directors of the American Psychedelic Practitioners Association. Jordan’s interdisciplinary perspective is informed by prior training in medical anthropology and global health, and deep interests in ceremonial uses of plant medicines, Buddhist philosophy, and integrative approaches to wellness.
Last Updated on January 21, 2026.
Appointments
Education & Training
- Research Fellow
- Yale University / West Haven VA (2021)
- Resident Physician
- Yale University School of Medicine (2018)
- MD
- Yale University School of Medicine (2014)
- MSc
- University of Edinburgh, Medical Anthropology (2007)
- BSc
- University of Winnipeg, Bioanthropology (2005)
Research
Copy Link
Overview
My research has investigated the efficacy and potential neurobiological and psychological mechanisms of psilocybin therapy for depression, and how psilocybin and ketamine can be integrated with evidence-based psychotherapies.
ORCID
0000-0001-7709-5931
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jordan Sloshower's published research.
Publications Timeline
A big-picture view of Jordan Sloshower's research output by year.
Deepak Cyril Dsouza, MBBS, MD
Brian Pittman
Emmanuelle Schindler, MD, PhD
Gabrielle Agin-Liebes, PhD
Gerard Sanacora, PhD, MD
Katrin Preller
22Publications
900Citations
Publications
Featured Publications
Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees
Prueitt WL, Sloshower J. Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees. Academic Psychiatry 2022, 47: 74-77. PMID: 35616783, PMCID: PMC9134971, DOI: 10.1007/s40596-022-01662-9.Peer-Reviewed Original ResearchCitationsAltmetricResearch abuses against people of colour and other vulnerable groups in early psychedelic research
Strauss D, de la Salle S, Sloshower J, Williams MT. Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal Of Medical Ethics 2021, 48: 728-737. PMID: 34253622, DOI: 10.1136/medethics-2021-107262.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSubstance use disordersDrug administration conditionsPsychedelic researchMental health issuesEthnicity of participantsUse disordersMental healthHealth issuesVulnerable populationsPsychedelic medicineVulnerable groupsResearch abusesFuture studiesAdministration conditionsAbuseCurrent ethical standardsFirst waveVariables of interestParticipantsFindingsPsilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame
Sloshower J, Guss J, Krause R, Wallace R, Williams M, Reed S, Skinta M. Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal Of Contextual Behavioral Science 2020, 15: 12-19. DOI: 10.1016/j.jcbs.2019.11.002.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMajor depressive disorderClinical trialsDepressive disorderPsychedelic-assisted therapyPsilocybin-assisted therapyCommitment TherapyRecent clinical trialsSmall clinical trialsDosing sessionsNeurobiological actionsPsilocybin therapyEvidence-based modelTherapyTherapy protocolsPsilocybin experiencePotential synergismDrug experienceTherapy sessionsTreatment modelClinical processesTrialsDisordersPsychological flexibilityMechanisms of changeACT processesIntegrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic
Sloshower J. Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic. 2018, 113-132. DOI: 10.1007/978-3-319-76720-8_7.ChaptersCitationsConceptsHealing paradigmPsychiatric practiceCurrent psychiatric practicePsychedelic substancesSymptom-focused treatmentEthical challengesReductionist tendenciesCritical dialogueHuman beingsPsychedelic medicineReflexive mannerModel clinicTherapeutic narrativesMental illnessParadigm integrationBiological paradigmMedical SciencesSufferingRelated practicesKnowledge generationPassive recipientsPracticeEnergetic domainsSuch challengesParadigmPsilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Sloshower J, Skosnik P, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal Of Psychopharmacology 2023, 37: 698-706. PMID: 36938991, DOI: 10.1177/02698811231154852.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMajor depressive disorderAntidepressant effectsDepressive disorderSevere major depressive disorderPsilocybin-assisted therapyEarly phase studiesQuality of lifeClinical improvementDosing sessionsMajor depressionPsilocybin administrationPlacebo effectPsychotherapeutic supportPlaceboTherapy effectsStudy periodPsychotherapy studiesFurther studiesSignificant differencesDepressionDosingTherapyHigh rateEffect sizeDegree of changeSub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms
Skosnik P, Sloshower J, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal Of Psychopharmacology 2023, 37: 687-697. PMID: 37392016, DOI: 10.1177/02698811231179800.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAntidepressant effectsTheta powerMajor depressive disorderEffects of psilocybinSub-acute effectsLong-term alterationsMeasures of depressionSingle doseDepressive disorderMajor depressionDepressive symptomsPlaceboSymptoms 2Depression symptomsEEG theta powerNeural plasticityNeuroplasticityEEG biomarkersSymptomsSerotonergic psychedelicsPotential mechanismsDepressionSustained changesElectroencephalographic correlatesPsilocybinThe DEA report on ayahuasca risks: “Science” in service of prohibition?
Labate B, Ermakova A, Sloshower J, Galvão-Coelho N, Palhano-Fontes F, Antunes H, Loures de Assis G, Cavnar C, de Araújo D, Ribeiro S. The DEA report on ayahuasca risks: “Science” in service of prohibition? Journal Of Psychedelic Studies 2023, 7: 81-89. DOI: 10.1556/2054.2023.00279.Peer-Reviewed Original ResearchCitationsAltmetricSingle-Dose Psilocybin Treatment for Major Depressive Disorder
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA: The Journal Of The American Medical Association 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMajor depressive disorderSheehan Disability Scale scoresAdverse eventsDisability scale scorePsilocybin treatmentDay 43Scale scoreSecondary outcomesSingle doseDepressive disorderExclusion criteriaPsychological supportMontgomery-Asberg Depression Rating Scale scoreSerious treatment-emergent adverse eventsDay 8Key secondary outcome measuresTreatment-emergent adverse eventsDepression Rating Scale scoresActive substance use disorderFifth Edition diagnosisIdentical-appearing capsulesOverall adverse eventsPhase 2 trialSerious adverse eventsSevere adverse eventsNavigating the mainstreaming of psychedelics
Labate B, Antunes H, Beachy J, Sloshower J, Cavnar C. Navigating the mainstreaming of psychedelics. Journal Of Psychedelic Studies 2025, 9: 108-115. DOI: 10.1556/2054.2024.00429.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPsychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
Sloshower J, Zeifman R, Guss J, Krause R, Safi-Aghdam H, Pathania S, Pittman B, D’Souza D. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Scientific Reports 2024, 14: 8833. PMID: 38632313, PMCID: PMC11024097, DOI: 10.1038/s41598-024-58318-x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPsilocybin-assisted therapyPsychological flexibilityDepression severityModerate to severe MDDSpectrum of neuropsychiatric conditionsTarget psychological flexibilityIncrease psychological flexibilityMental health conditionsManualized psychotherapyPsilocybin treatmentSevere MDDDepressive disorderExperiential acceptanceCommitment TherapyDosing sessionsNeuropsychiatric conditionsPsychedelic trialsPlacebo-controlled trialWithin-subjectMDDPsilocybinAdministered placeboPlacebo-ControlledDepressionClinical samples
Academic Achievements & Community Involvement
Copy Link
Activities
activity Advisory Board
2022 - PresentAdvisory BoardsFaculty AdvisorDetailsChacruna Instituteactivity American Psychedelic Practitioners Association (APPA)
2022 - 2023Public ServiceBoard of Directors
News
Copy Link
News
- April 23, 2024Source: Scientific Reports
Psychological Flexibility as a Mechanism of Change in Psilocybin-Assisted Therapy for Major Depression: Results From an Exploratory Placebo-Controlled Trial
- June 20, 2023Source: New Haven Independent
Whalley Wellness Center Explores Therapy’s Frontier
- March 24, 2023Source: Journal of Psychopharmacology
Psilocybin-Assisted Therapy for Major Depressive Disorder: An Exploratory Placebo-Controlled, Fixed-Order Trial
Get In Touch
Copy Link